BRPI0814448A2 - processo de produção de trazodona e cloridrato de trazodona, trazodona e cloridrato de trazodona, e, composição farmacêutica - Google Patents

processo de produção de trazodona e cloridrato de trazodona, trazodona e cloridrato de trazodona, e, composição farmacêutica

Info

Publication number
BRPI0814448A2
BRPI0814448A2 BRPI0814448A BRPI0814448A BRPI0814448A2 BR PI0814448 A2 BRPI0814448 A2 BR PI0814448A2 BR PI0814448 A BRPI0814448 A BR PI0814448A BR PI0814448 A BRPI0814448 A BR PI0814448A BR PI0814448 A2 BRPI0814448 A2 BR PI0814448A2
Authority
BR
Brazil
Prior art keywords
trazodone
hydrochloride
pharmaceutical composition
production process
trazodone hydrochloride
Prior art date
Application number
BRPI0814448A
Other languages
English (en)
Inventor
Giovanni Battista Ciottoli
Giuseppe Biondi
Marcello Marchetti
Tommaso Iacoangeli
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39064326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0814448(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acraf filed Critical Acraf
Publication of BRPI0814448A2 publication Critical patent/BRPI0814448A2/pt
Publication of BRPI0814448B1 publication Critical patent/BRPI0814448B1/pt
Publication of BRPI0814448B8 publication Critical patent/BRPI0814448B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
BRPI0814448A 2007-08-03 2008-07-23 processo de produção de trazodona e cloridrato de trazodona BRPI0814448B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITMI2007A001603 2007-08-03
IT001603A ITMI20071603A1 (it) 2007-08-03 2007-08-03 Trazodone e trazodone cloridrato in forma purificata
US97653507P 2007-10-01 2007-10-01
US60/976535 2007-10-01
PCT/EP2008/059640 WO2009019133A1 (en) 2007-08-03 2008-07-23 Trazodone and trazodone hydrochloride in purified form

Publications (3)

Publication Number Publication Date
BRPI0814448A2 true BRPI0814448A2 (pt) 2016-07-26
BRPI0814448B1 BRPI0814448B1 (pt) 2019-04-02
BRPI0814448B8 BRPI0814448B8 (pt) 2021-05-25

Family

ID=39064326

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814448A BRPI0814448B8 (pt) 2007-08-03 2008-07-23 processo de produção de trazodona e cloridrato de trazodona

Country Status (22)

Country Link
US (20) US8133893B2 (pt)
EP (1) EP2178850B1 (pt)
JP (3) JP5635401B2 (pt)
KR (2) KR20140133901A (pt)
CN (1) CN101772490B (pt)
AR (1) AR067773A1 (pt)
BR (1) BRPI0814448B8 (pt)
CA (1) CA2693095C (pt)
CY (1) CY1115666T1 (pt)
DK (1) DK2178850T3 (pt)
EA (1) EA017019B1 (pt)
ES (1) ES2517871T3 (pt)
GE (2) GEP20135915B (pt)
HR (1) HRP20140978T1 (pt)
IL (2) IL203294A (pt)
IT (1) ITMI20071603A1 (pt)
MX (1) MX2010001094A (pt)
PL (1) PL2178850T3 (pt)
PT (1) PT2178850E (pt)
SI (1) SI2178850T1 (pt)
UA (1) UA103597C2 (pt)
WO (1) WO2009019133A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20071573A1 (it) 2007-07-31 2009-02-01 Acraf Composizione farmaceutica liquida stabile a base di trazodone
ITMI20071603A1 (it) * 2007-08-03 2009-02-04 Acraf Trazodone e trazodone cloridrato in forma purificata
WO2012072665A1 (en) 2010-11-30 2012-06-07 Pharmaneuroboost N.V. Compositions comprising pipamperone and serotonin antagonist reuptake inhibitors
CN103853790B (zh) * 2012-12-06 2016-04-06 腾讯科技（深圳）有限公司 移动终端浏览器的上传信息处理方法及装置
IN2014MU00203A (pt) * 2014-01-21 2015-09-25 Piramal Entpr Ltd
CN105777745A (zh) * 2016-03-29 2016-07-20 深圳市泛谷药业股份有限公司 一种盐酸曲唑酮的制备方法
UA126870C2 (uk) * 2018-02-07 2023-02-15 Ацьєнде Кіміке Ріуніте Анджеліні Франческо А.Чі.Р.А.Ф. С.П.А. Безперервний спосіб одержання тразодону
RU2706700C1 (ru) 2019-09-24 2019-11-20 Общество с ограниченной ответственностью "Научно-производственная компания "СКиФФ" Фармацевтическая композиция для коррекции поведения кошек и собак в стрессовых ситуациях
WO2021058810A1 (en) 2019-09-26 2021-04-01 Angelini S.P.A. Pediatric trazodone compositions and method of treatment thereof
CN117517545A (zh) * 2023-12-08 2024-02-06 重庆锐恩医药有限公司 一种盐酸曲唑酮有关物质检测方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR8135E (fr) 1844-10-05 1846-07-28 Millet et Bonheur Pour un tissu imperméable
GB1117068A (en) * 1965-12-15 1968-06-12 Acraf S-triazole-[4,3-a]-pyridine derivatives and processes for their preparation
IT1066857B (it) * 1965-12-15 1985-03-12 Acraf Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
FR8135M (pt) * 1968-12-31 1970-08-10
IT1047702B (it) * 1975-07-24 1980-10-20 Acraf Nuova sintesi degli psicofarmaci denominati trazodone ed eteroperidone
US4465683A (en) * 1979-09-14 1984-08-14 Mead Johnson & Company Anti-psychotic agents
US4254124A (en) * 1979-09-24 1981-03-03 Mead Johnson & Company Antidepressant agent
US4252806A (en) * 1979-09-24 1981-02-24 Mead Johnson & Company Triazoloquinolones
IT1211095B (it) * 1981-08-17 1989-09-29 Roma Aziende Chimiche Riunite Impiego del trazodone nel trattamento delle ulcere gastroduodenali.
IT1233412B (it) * 1987-12-02 1992-03-30 Acraf Uso del trazodone
IT1314283B1 (it) * 1999-12-16 2002-12-06 Acraf Trazodone cloridrato ed un procedimento per prepararlo.
EA008705B1 (ru) * 2003-04-08 2007-06-29 Алгоркс Фармасьютикалз, Инк. Получение и очистка синтетического капсаицина
EA014739B1 (ru) * 2005-09-09 2011-02-28 Лабофарм Инк. Композиция тразодона для введения один раз в день
ITMI20071573A1 (it) 2007-07-31 2009-02-01 Acraf Composizione farmaceutica liquida stabile a base di trazodone
ITMI20071603A1 (it) * 2007-08-03 2009-02-04 Acraf Trazodone e trazodone cloridrato in forma purificata

Also Published As

Publication number Publication date
WO2009019133A1 (en) 2009-02-12
CY1115666T1 (el) 2017-01-25
AR067773A1 (es) 2009-10-21
CN101772490B (zh) 2013-11-06
BRPI0814448B1 (pt) 2019-04-02
GEP20135915B (en) 2013-08-26
AU2008285779A1 (en) 2009-02-12
IL225873A (en) 2016-10-31
JP2010535170A (ja) 2010-11-18
JP2014221788A (ja) 2014-11-27
ES2517871T3 (es) 2014-11-04
US20190231774A1 (en) 2019-08-01
US20150297589A1 (en) 2015-10-22
BRPI0814448B8 (pt) 2021-05-25
US20140057922A1 (en) 2014-02-27
US20210052577A1 (en) 2021-02-25
US20130203771A1 (en) 2013-08-08
EA017019B1 (ru) 2012-09-28
CA2693095A1 (en) 2009-02-12
PT2178850E (pt) 2014-10-07
MX2010001094A (es) 2010-03-01
US20260108508A1 (en) 2026-04-23
US20100056539A1 (en) 2010-03-04
KR20140133901A (ko) 2014-11-20
IL203294A (en) 2013-05-30
HRP20140978T1 (hr) 2014-12-05
ITMI20071603A1 (it) 2009-02-04
US20170333425A1 (en) 2017-11-23
US20200253965A1 (en) 2020-08-13
US20160113926A1 (en) 2016-04-28
JP5635401B2 (ja) 2014-12-03
PL2178850T3 (pl) 2015-03-31
KR101505522B1 (ko) 2015-03-30
US20130012520A1 (en) 2013-01-10
US20160324853A1 (en) 2016-11-10
UA103597C2 (xx) 2013-11-11
EP2178850B1 (en) 2014-09-03
US20180161323A1 (en) 2018-06-14
US8133893B2 (en) 2012-03-13
SI2178850T1 (sl) 2014-12-31
DK2178850T3 (en) 2014-11-17
EP2178850A1 (en) 2010-04-28
GEP20135926B (en) 2013-10-10
CA2693095C (en) 2015-11-24
US20180353503A1 (en) 2018-12-13
US20140296250A1 (en) 2014-10-02
US20120142699A1 (en) 2012-06-07
HK1139405A1 (en) 2010-09-17
US20200038396A1 (en) 2020-02-06
US8314236B2 (en) 2012-11-20
EA201070228A1 (ru) 2010-06-30
JP6513911B2 (ja) 2019-05-15
JP2017141246A (ja) 2017-08-17
KR20100046245A (ko) 2010-05-06
US20150105402A1 (en) 2015-04-16
US20170128442A1 (en) 2017-05-11
IL225873A0 (en) 2013-06-27
CN101772490A (zh) 2010-07-07
US20240139179A1 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
BRPI0718339A2 (pt) Composto, composição, composição farmacêutica e processo de fabricação de tanato de rasagilina
BRPI0810632A2 (pt) Derivados de piridopirazina, processo de fabricação e usos dos mesmos
BRPI0720068A2 (pt) Processo para preparar nanocápsulas, produto, nanocápsulas e composição
BRPI0820139A2 (pt) Composição antiperspirante ativa, e, processo de obtenção de uma composição antiperspirante ativa
BRPI0821944A2 (pt) Processo
BRPI0906249A2 (pt) Processo de elaboração de 1,1,1,4,4,4-hexafluoro-2-buteno
BRPI0919868A2 (pt) processo
BRPI0818887A2 (pt) Processo de produção de açúcares
BRPI0821445A2 (pt) Folha, processo de fabricação de uma folha, e, artigo
BRPI0916588A2 (pt) cobertor, produtos correlacionados e métodos de produção dos mesmos
BRPI0921374A2 (pt) processo
BRPI0914221A2 (pt) processo, e, composto
BR112012000821A2 (pt) "processo"
BRPI0821801A2 (pt) Zeólito e processo de preparação de um zeólito.
EP2095426A4 (en) NANOELECTRIC STRUCTURE AND MANUFACTURING METHOD THEREFOR
PT2165971T (pt) Processo de hidrotratamento
BRPI0806679A2 (pt) Processo aperfeiçoado de produção de alquilaromático
BRPI0815784A2 (pt) Processo para a preparação de 1,2-propanodiol
BRPI0918980A2 (pt) Produto de confeitaria, processo e aparelho de produção
BRPI0910545A2 (pt) processo contínuo para fazer composições farmacêuticas
HRP20170959T1 (hr) Farmaceutska suspenzija
BRPI0813960A2 (pt) Processo para produção de biarilas
BRPI1016039A2 (pt) processo, e, composição antimascaramento.
BRPI0815971A2 (pt) Processo para a preparação de 1,2-propanodiol
BR112012002403A2 (pt) polímero supramolecular, processo de síntese de polímero supramolecular, composição e artigos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/07/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF